South Korea · Delayed Price · Currency is KRW Bio Plus Statistics
Total Valuation
Bio Plus has a market cap or net worth of KRW 198.16 billion. The enterprise value is 256.36 billion.
| Market Cap | 198.16B |
| Enterprise Value | 256.36B |
Important Dates
The next estimated earnings date is Friday, November 13, 2026.
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | Dec 29, 2025 |
Share Statistics
Bio Plus has 61.54 million shares outstanding. The number of shares has increased by 10.34% in one year.
| Current Share Class | 61.54M |
| Shares Outstanding | 61.54M |
| Shares Change (YoY) | +10.34% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 29.20% |
| Owned by Institutions (%) | 5.05% |
| Float | 43.16M |
Valuation Ratios
The trailing PE ratio is 20.67.
| PE Ratio | 20.67 |
| Forward PE | n/a |
| PS Ratio | 2.00 |
| PB Ratio | 0.99 |
| P/TBV Ratio | 1.17 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 10.65 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 18.52 |
| EV / Sales | 2.59 |
| EV / EBITDA | 11.54 |
| EV / EBIT | 14.49 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.95, with a Debt / Equity ratio of 0.33.
| Current Ratio | 0.95 |
| Quick Ratio | 0.60 |
| Debt / Equity | 0.33 |
| Debt / EBITDA | 2.95 |
| Debt / FCF | -251.32 |
| Interest Coverage | 58.71 |
Financial Efficiency
Return on equity (ROE) is 10.65% and return on invested capital (ROIC) is 7.56%.
| Return on Equity (ROE) | 10.65% |
| Return on Assets (ROA) | 3.90% |
| Return on Invested Capital (ROIC) | 7.56% |
| Return on Capital Employed (ROCE) | 7.89% |
| Weighted Average Cost of Capital (WACC) | 5.72% |
| Revenue Per Employee | 615.85M |
| Profits Per Employee | 86.00M |
| Employee Count | 161 |
| Asset Turnover | 0.35 |
| Inventory Turnover | 2.16 |
Taxes
| Income Tax | -2.30B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -47.73% in the last 52 weeks. The beta is 0.59, so Bio Plus's price volatility has been lower than the market average.
| Beta (5Y) | 0.59 |
| 52-Week Price Change | -47.73% |
| 50-Day Moving Average | 3,600.70 |
| 200-Day Moving Average | 4,830.50 |
| Relative Strength Index (RSI) | 33.09 |
| Average Volume (20 Days) | 192,659 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Bio Plus had revenue of KRW 99.15 billion and earned 13.85 billion in profits. Earnings per share was 155.76.
| Revenue | 99.15B |
| Gross Profit | 67.93B |
| Operating Income | 17.72B |
| Pretax Income | 17.49B |
| Net Income | 13.85B |
| EBITDA | 22.24B |
| EBIT | 17.72B |
| Earnings Per Share (EPS) | 155.76 |
Balance Sheet
The company has 29.35 billion in cash and 65.65 billion in debt, with a net cash position of -36.31 billion or -589.99 per share.
| Cash & Cash Equivalents | 29.35B |
| Total Debt | 65.65B |
| Net Cash | -36.31B |
| Net Cash Per Share | -589.99 |
| Equity (Book Value) | 200.33B |
| Book Value Per Share | 2,899.49 |
| Working Capital | -3.76B |
Cash Flow
In the last 12 months, operating cash flow was 18.61 billion and capital expenditures -18.87 billion, giving a free cash flow of -261.24 million.
| Operating Cash Flow | 18.61B |
| Capital Expenditures | -18.87B |
| Depreciation & Amortization | 4.51B |
| Net Borrowing | 2.46B |
| Free Cash Flow | -261.24M |
| FCF Per Share | -4.24 |
Margins
Gross margin is 68.51%, with operating and profit margins of 17.88% and 13.96%.
| Gross Margin | 68.51% |
| Operating Margin | 17.88% |
| Pretax Margin | 17.64% |
| Profit Margin | 13.96% |
| EBITDA Margin | 22.43% |
| EBIT Margin | 17.88% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 70.00, which amounts to a dividend yield of 2.09%.
| Dividend Per Share | 70.00 |
| Dividend Yield | 2.09% |
| Dividend Growth (YoY) | 40.00% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 30.99% |
| Buyback Yield | -10.34% |
| Shareholder Yield | -8.26% |
| Earnings Yield | 6.99% |
| FCF Yield | -0.13% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on November 23, 2022. It was a forward split with a ratio of 4.
| Last Split Date | Nov 23, 2022 |
| Split Type | Forward |
| Split Ratio | 4 |
Scores
Bio Plus has an Altman Z-Score of 3.15 and a Piotroski F-Score of 6.
| Altman Z-Score | 3.15 |
| Piotroski F-Score | 6 |